1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2

A compound of formula I:

• in which:
• m is selected from 0, 1 and 2;
• p is 1;
• Y1 is selected from CH and N;
• Y2 is selected from CR6 and N;
• Y3 is CR7R8;
• R1 is selected from C6-10aryl, C3-8cycloalkyl, C3-8cycloalkenyl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms selected from N, O and S;
• wherein said aryl or heteroaryl of R1 is substituted with 1 to 5 R9 groups independently selected from halo, amino, hydroxy, N3, C1-4 alkyl, C1-4alkoxy, hydroxy-substituted-C1-4alkyl, halo-substituted-C1-4alkyl, amino-substituted-C1-4alkyl, —C(O)OR10 and —NHC(O)R10;
• R10 is selected from hydrogen, phenyl and naphthyl;
• wherein said phenyl of R10 is unsubstituted or substituted with methoxy;
• R2a and R2b are independently selected from hydrogen, C1-4alkyl, C1-4alkoxy, amino, hydroxy, C3-8cycloalkyl and C1-4alkyl-amino;
• R3a and R3b are independently selected from hydrogen, halo, carbonyl, C1-4 alkyl, C1-4alkoxy, amino, hydroxy, C3-8cycloalkyl and C1-4 alkyl-amino;
• R4a and R4b are independently selected from hydrogen, halo, carbonyl, C1-4 alkyl, C1-4alkoxy, amino, hydroxy, C3-8cycloalkyl and C1-4alkyl-amino;
• R5a and R5b are independently selected from hydrogen, carbonyl, C1-4alkyl, C1-4alkoxy, amino, hydroxy, C3-8cycloalkyl and C1-4alkyl-amino;
• wherein any two groups selected from R2a, R3a, R4a and R7 can form a 5 to 6 member unsaturated, partially unsaturated ring or saturated ring optionally containing a ring nitrogen;
• R6 is selected from hydrogen, halo, cyano, C1-4alkyl, C1-4alkoxy, amino-carbonyl, halo-substituted C1-4alkyl, halo-substituted C1-4alkoxy, hydroxy-substituted C1-4alkyl, amino-substituted C1-4 alkyl, —S(O)1-2R6a, —C(S)R6a, —C(O)NR6aR6b, —C(NH)NR6aR6b and —NR6aC(O)R6b;
• wherein R6a and R6b are independently selected from hydrogen and C1-4alkyl;
• R7 is selected from hydrogen, C1-4alkyl, C3-6cycloalkyl, C6-10aryl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms selected from N, O and S;
• or R7 and R4a together with the carbon atoms to which they are both attached can form a pyrrolidinyl or cyclopropyl group optionally substituted with amino;
• R8 is selected from amino, amino-methyl and methyl-amino;
• or a pharmaceutically acceptable salt thereof.